Benidipine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Benidipine
Accession Number
DB09231
Type
Small Molecule
Groups
Approved, Investigational
Description

Benidipine (INN) is a dihydropyridine calcium channel blocker for the treatment of high blood pressure (hypertension). It is a triple L-, T-, and N- type calcium channel blocker. It is reno- and cardioprotective.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Benidipine hydrochloride0A6746FWDL91599-74-5KILKDKRQBYMKQX-MIPPOABVSA-N
International/Other Brands
Coniel (Kyowa Hakko Kogyo)
Categories
UNII
4G9T91JS7E
CAS number
105979-17-7
Weight
Average: 505.571
Monoisotopic: 505.22128573
Chemical Formula
C28H31N3O6
InChI Key
QZVNQOLPLYWLHQ-ZEQKJWHPSA-N
InChI
InChI=1S/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1
IUPAC Name
3-(3R)-1-benzylpiperidin-3-yl 5-methyl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C([[email protected]@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[[email protected]@H]1CCCN(CC2=CC=CC=C2)C1

Pharmacology

Indication

For the treatment of hypertension.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Benidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Benidipine.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Benidipine.Approved, Investigational
AmobarbitalThe metabolism of Benidipine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Benidipine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Benidipine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Benidipine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Benidipine.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Benidipine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Benidipine is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Benidipine.Experimental
BarbexacloneThe metabolism of Benidipine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Benidipine can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Benidipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Benidipine.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Benidipine.Experimental
BucindololBucindolol may increase the hypotensive activities of Benidipine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Benidipine.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Benidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Benidipine.Approved
Calcium AcetateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Benidipine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Benidipine.Experimental
CarbomycinThe metabolism of Benidipine can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Benidipine.Approved, Investigational
CaseinThe therapeutic efficacy of Benidipine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Benidipine.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Benidipine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Benidipine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Benidipine.Approved, Investigational
CimetidineThe serum concentration of Benidipine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Benidipine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Benidipine.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Benidipine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Benidipine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Benidipine.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Benidipine.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Benidipine.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Benidipine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Benidipine.Approved
EfavirenzThe serum concentration of Benidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Benidipine.Approved
ErythromycinThe metabolism of Benidipine can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Benidipine.Experimental
FluconazoleThe serum concentration of Benidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Benidipine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Benidipine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Benidipine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Benidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Benidipine.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Benidipine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Benidipine.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Benidipine.Approved, Investigational
HexobarbitalThe metabolism of Benidipine can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Benidipine.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Benidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Benidipine.Approved, Investigational
JosamycinThe metabolism of Benidipine can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Benidipine.Approved, Investigational
KitasamycinThe metabolism of Benidipine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Benidipine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Benidipine.Experimental
MethohexitalThe metabolism of Benidipine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Benidipine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Benidipine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Benidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Benidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Benidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Benidipine.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Benidipine.Experimental
NafcillinThe metabolism of Benidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Benidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Benidipine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Benidipine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Benidipine.Investigational
NitroprussideBenidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Benidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Benidipine.Approved, Vet Approved
OleandomycinThe metabolism of Benidipine can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Benidipine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Benidipine.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Benidipine.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Benidipine.Approved
PentobarbitalThe metabolism of Benidipine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Benidipine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Benidipine.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Benidipine.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Benidipine.Approved
PrimidoneThe metabolism of Benidipine can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Benidipine.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Benidipine.Experimental
RifabutinThe serum concentration of Benidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Benidipine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Benidipine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Benidipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Benidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Benidipine.Approved, Vet Approved
SecobarbitalThe metabolism of Benidipine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Benidipine.Approved
SilodosinSilodosin may increase the hypotensive activities of Benidipine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Benidipine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Benidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Benidipine.Approved, Investigational
SolithromycinThe metabolism of Benidipine can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Benidipine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Benidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Benidipine.Approved
TelithromycinThe metabolism of Benidipine can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Benidipine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Benidipine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Benidipine.Approved
ThiamylalThe metabolism of Benidipine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Benidipine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Benidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Benidipine.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Benidipine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Benidipine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Benidipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Benidipine.Approved, Investigational
TylosinThe metabolism of Benidipine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Benidipine is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Benidipine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Benidipine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
656668
PubChem Substance
310265135
ChemSpider
571013
ChEMBL
CHEMBL2105555
Wikipedia
Benidipine
ATC Codes
C08CA15 — Benidipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentChronic Kidney Disease (CKD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00243 mg/mLALOGPS
logP4.28ALOGPS
logP4.02ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)19.47ChemAxon
pKa (Strongest Basic)7.89ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area111.01 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity141 m3·mol-1ChemAxon
Polarizability53.53 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-benzylpiperidines. These are heterocyclic Compounds containing a piperidine ring conjugated to a benzyl group through one nitrogen ring atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Benzylpiperidines
Direct Parent
N-benzylpiperidines
Alternative Parents
Dihydropyridinecarboxylic acids and derivatives / Nitrobenzenes / Phenylmethylamines / Benzylamines / Nitroaromatic compounds / Aralkylamines / Dicarboxylic acids and derivatives / Vinylogous amides / Methyl esters / Enoate esters
show 12 more
Substituents
N-benzylpiperidine / Nitrobenzene / Dihydropyridinecarboxylic acid derivative / Phenylmethylamine / Nitroaromatic compound / Benzylamine / Dihydropyridine / Aralkylamine / Monocyclic benzene moiety / Benzenoid
show 32 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 10:16 / Updated on December 01, 2017 17:21